Evidence based study of Hypoglycemic Potential of Bitter Melon Peptide |Biomedgrid

Momordica charantia (M. charantia), commonly referred to as bitter melon was received much attention for its anti-diabetic properties in recent years. The aim of this review was to discuss the bioactive peptides in bitter melon through their in vitro, in vivo and clinical studies for diabetes. Research showed that bitter melon peptides acted as the α-amylase or α-glycosidase inhibitor delayed the absorption of glucose from carbohydrates. Another noteworthy mechanism was the glucose intake regulation by insulin-like activities to enhanced insulin receptor kinase activity which activated IR signaling transduction pathway, resulted the translocation of glucose transporter 4, and uptake of glucose to cells. The remarkable effect of bitter melon peptide (mcIRBP-19) in patients with diabetes was also reported in the clinical study. This study summarized the scientific evidence of bitter melon peptides in regulating blood sugar levels through bioactive mechanisms. The bioactive peptides from bitter melon might open up new opportunities for the management of diabetes.